Allogene MSCs Transplantation in Patients With Chronic Liver Diseases Through Peripheral Vein.

December 7, 2010 updated by: Sun Yat-sen University

Therapeutic Effects of Allogene MSCs Transplantation in Patients With Chronic Liver Diseases Through Peripheral Vein.

Allogene MSCs transplantation will be performed in patients with chronic liver diseases through peripheral vein and therapeutic effects including short-term effects and long-term follow-up will be compared and investigated.

Study Overview

Study Type

Observational

Enrollment (Anticipated)

60

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Guangdong
      • GuangZhou, Guangdong, China, 510630
        • Recruiting
        • Department of Infectious Diseases, 3rd Affiliated Hospital of Sun Yat-sen University
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years to 65 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients with chronic liver diseases including: viral hepatitis, alcoholic liver disease, autoimmune liver disease and so on.

Description

Inclusion Criteria:

  1. chronic liver diseases including: viral hepatitis, alcoholic liver disease, autoimmune liver disease.
  2. age: 15-65 years old.

Exclusion Criteria:

  1. pregnant women and women in lactation.
  2. other systems and organs disfunction
  3. space-occupying lesion were found in liver.
  4. concurrent infection with HIV and other immunodeficiency diseases.
  5. DIC and active bleeding were confirmed.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Allogene MSCs transplantation
Allogene MSCs transplantation were performed in patients with chronic liver diseases through peripheral vein plus the same medical treatments.
control
only medical treatments were performed in patients with chronic liver diseases.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Short-term therapeutic effects at 1-8 weeks after Allogene MSCs transplantation through peripheral vein.
Time Frame: 1-8 weeks after transplantation
1-8 weeks after transplantation

Secondary Outcome Measures

Outcome Measure
Time Frame
Long-term follow-up of Allogene MSCs transplantation through peripheral vein.
Time Frame: 3-60 months
3-60 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2010

Study Registration Dates

First Submitted

December 7, 2010

First Submitted That Met QC Criteria

December 7, 2010

First Posted (Estimate)

December 8, 2010

Study Record Updates

Last Update Posted (Estimate)

December 8, 2010

Last Update Submitted That Met QC Criteria

December 7, 2010

Last Verified

October 1, 2010

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SunYat-sen U 11-5-1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Allogene MSCs Transplantation

3
Subscribe